Marksans Pharma Limited — Results, 11-02-2025: Integrated Filing- Financial

Marksans Pharma Limited reported its financial results for the quarter and nine months ended December 31, 2024. The consolidated revenue from operations reached ₹6,818.46 million, reflecting a positive trajectory compared to previous periods. Net profit after tax stood at ₹1,050.67 million, indicating strong profitability, while the earnings per share were recorded at ₹2.31. The results showcase the effectiveness of the company’s operations in the pharmaceutical segment amidst a competitive landscape. Investors may view this robust performance as indicative of a positive outlook, potentially bolstering confidence in the firm's future growth and financial stability.